Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia
Date
2010
Authors
Sulda, M.L.
Kuss, B.J.
Hall, R.K.
Bailey, S.
Macardle, P.J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Internal Medicine Journal, 2010; 42(2):137-146
Statement of Responsibility
Conference Name
Abstract
Background: Chronic lymphocytic leukaemia (CLL) is a clinically heterogeneous disease. While immunoglobulin variable region heavy chain (IgVH) mutational status remains the ‘gold standard’ in molecular prognostication, a range of additional markers is increasingly being used in clinical trials. As awareness of trial data increases, requests to determine these prognostic markers for new CLL patients are becoming more prevalent in Australia.
Aim: To explore the clinical utility of currently available prognostic markers for CLL in an Australian cohort
Methods: IgVH mutational status and gene usage was determined and compared with other reported immunophenotypic markers, cytogenetics and clinical outcome as defined by treatment-free survival (TFS), lymphocyte doubling time andclinical stage in a cohort of 65 CLL patients
Results: An unmutated IgVH gene, high expression of CD38, ZAP-70, CD25, CD49d,CD54 or low expression of CD49c was associated with shorter TFS indicating an adverse clinical prognosis in our cohort. High expression of each of CD38, ZAP-70, CD49d and CD54 was significantly associated with an unmutated IgVH gene; however, associations were not absolute. IgVH and CD25 expression retained their significance in multivariate analysis. Concordant CD25high/IgVH unmutated CLL patients had the shortest medianTFS interval (40 months) in our cohort
Conclusions: Molecular and immunophenotypic markers remain useful as adjuncts to clinical prognostication; however, as single parameters they are unable to dictate the timing of therapeutic intervention. The combined use of CD25 and IgVH mutationalstatus may be clinically relevant to CLL prognostication while also providing insight intothe biological pathways involved in disease progression
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2010 The Authors